A generally accepted hypothesis for the initial activation of an immune or autoimmune response argues that alarmins are released from injured, dying and/or activated immune cells, and these products complex with receptors that activate signal transduction pathways and recruit immune cells to the site of injury where the recruited cells are stimulated to initiate immune and/or cellular repair responses. While there are multiple diverse families of alarmins such as interleukins (IL), heat-shock proteins (HSP), Toll-like receptors (TLR), plus individual molecular entities such as Galectin-3, Calreticulin, Thymosin, alpha-Defensin-1, RAGE, and Interferon-1, one phylogenetically conserved family are the Annexin proteins known to promote an extensive range of biomolecular and cellular products that can directly and indirectly regulate inflammation and immune activities. For the present report, we examined the temporal expression profiles of the 12 mammalian annexin genes ( and ), applying our temporal genome-wide transcriptome analyses of ex vivo salivary and lacrimal glands from our C57BL/6.NOD- mouse model of Sjögren's Syndrome (SS), a human autoimmune disease characterized primarily by severe dry mouth and dry eye symptoms. Results indicate that annexin genes and exhibited upregulated expressions and the initial timing for these upregulations occurred as early as 8 weeks of age and prior to any covert signs of a SS-like disease. While the profiles of the two glands were similar, they were not identical, suggesting the possibility that the SS-like disease may not be uniform in the two glands. Nevertheless, this early pre-clinical and concomitant upregulated expression of this specific set of alarmins within the immune-targeted organs represents a potential target for identifying the pre-clinical stage in human SS as well, a fact that would clearly impact future interventions and therapeutic strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570365PMC
http://dx.doi.org/10.3390/ijms231911709DOI Listing

Publication Analysis

Top Keywords

lacrimal glands
8
c57bl/6nod- mouse
8
immune cells
8
annexin genes
8
ss-like disease
8
immune
5
temporal comparative
4
comparative rna
4
rna transcriptome
4
transcriptome profile
4

Similar Publications

Orbital and adnexal sarcoidosis: Clinical presentations and management outcomes.

Indian J Ophthalmol

February 2025

Department of Orbit, Oculoplasty, Reconstructive and Aesthetic Services, Sankara Nethralaya, Medical Research Foundation, Chennai, Tamil Nadu, India.

Purpose: To present the clinical features and management outcomes in a series of patients with orbital and adnexal sarcoidosis.

Methods: This was a retrospective analysis of 19 histopathologically proven cases of orbital and adnexal sarcoidosis over the past ten years. The data analyzed included demographic details, clinical and imaging features, and management outcomes.

View Article and Find Full Text PDF

Purpose: To evaluate the lacrimal punctal changes in different age groups using anterior segment optical coherence tomography (AS-OCT).

Methods: A cross-sectional observational study was conducted between January 2023 and January 2024 including healthy subjects between 20 and 80 years. The selected eyes from healthy patients were divided into four age groups (21-35 years, 36-50 years, 51-65 years, 66-80 years), and lower lacrimal puncta were analyzed using AS-OCT.

View Article and Find Full Text PDF

Application of S-100 absorbable hemostatic patch in endonasal endoscopic dacryocystorhinostomy: A randomized controlled trial.

Indian J Ophthalmol

February 2025

Hainan Eye Hospital and Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Haikou, Hainan Province, China.

Purpose: To investigate the effect of S-100 absorbable hemostatic patch coverage on anastomotic mucosa in endonasal endoscopic dacryocystorhinostomy (En-DCR).

Methods: Two hundred and twenty-six patients with unilateral chronic dacryocystitis (CD) were randomly divided into two groups in a randomized controlled trial: the S-100 absorbable hemostatic patch group (group A) and the control group (group B). All patients underwent En-DCR.

View Article and Find Full Text PDF

Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.

View Article and Find Full Text PDF

Background: Epiphora and secondary ocular surface damage are increasingly impairing the quality of life of people, particularly elderly women. We aimed to investigate the changes in tear cytokine and lactoferrin levels in postmenopausal women with primary acquired nasolacrimal duct obstruction (PANDO) complicated with obstructed meibomian gland dysfunction (OMGD) and preliminary explore the pathological mechanisms of OMGD in patients with PANDO.

Methods: The prospective study involved 43 and 41 postmenopausal women with and without PANDO, respectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!